Daniel Yin

Dan is a member of our Life Sciences team, advising on innovations across small‑molecule pharmaceuticals, nucleic‑acid and antibody therapeutics, and protein engineering. He works closely with clients to understand their scientific and commercial objectives, providing tailored patent strategies across the full patent lifecycle, from drafting through to global prosecution.

He has significant experience in EPO oppositions and appeals, on cases relating to glycoprotein engineering, antibody manufacture, antibody-drug conjugates, stem cell therapy and culture methods, CAR‑T therapy, and enzymatic methods in agriculture.

Areas of Expertise

• Biochemistry
• Chemistry
• Pharmaceuticals
• Nucleic acid and protein therapeutics, including antibody-based therapeutics
• Protein engineering
• Medical devices

Clients

Dan works directly with a broad client base, including universities, start‑ups, and multinational pharma companies. He is also a trusted advisor to US and Japanese attorney firms, providing strategic guidance to secure and defend European patent protection for their clients.

Background

Dan holds a Master’s degree in Chemistry and a DPhil in Biochemistry from the University of Oxford, where he researched molecular switches and antimicrobial peptides. His postdoctoral research at the Dana‑Farber Cancer Institute, Harvard Medical School, focused on biologically active and chemically modified peptides.

Dan joined Mewburn Ellis LLP in 2017, qualifying as a European Patent Attorney in 2021 and a UK Patent Attorney in 2023.

Memberships & Affiliations

Dan is a member of the Chartered Institute of Patent Attorneys (CIPA) and the Institute of Professional Representatives before the EPO (epi).  He also sits on the International & Foreign Practice Committee for the Boston Intellectual Property Law Association (BIPLA).

He is a regular speaker on patenting strategy for London‑based university technology transfer offices, and also examines trainee patent attorneys in the UK.